dulaglutide vs Semaglutide (Ozempic)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
Reported efficacy
Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)
Result source: NCT03495102
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)
Result source: NCT03819153
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dulaglutide | Semaglutide (Ozempic) |
|---|---|---|
| HbA1c, change | -2.0% vs -1.1%−0.9 vs placeboNCT0459162625 other results
| -1.6% vs 0%−1.6 vs placeboNCT0205489735 other results
|
| Body weight, change (kg) | -0.8 vs 0.4−1.2 vs placeboNCT0459162618 other results
| -4.9 vs -0.6−4.3 vs placeboNCT0172044632 other results
|
| HbA1c below 7% | 75.9% vs 33.8%+42.1 vs placeboNCT045916268 other results
| 72.3% vs 24.8%+47.5 vs placeboNCT0205489710 other results
|
| Fasting plasma glucose, change | -2.2 vs -2.4vs Insulin GlargineNCT016485823 other results
| -2.1 vs -0.9−1.2 vs placeboNCT0172044624 other results
|
| 3-point MACE (% with event) | 12% vs 13.4%−1.4 vs placeboNCT013949521 other result
| 6.6% vs 8.9%−2.3 vs placeboNCT017204461 other result
|
HbA1c, change
- dulaglutide
- -2.0% vs -1.1%−0.9 vs placeboNCT04591626
25 other results
- -1.3% vs -0.5% NCT02597049
- -1.3% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.4% vs -0.7% NCT02152371
- -1.4% vs -0.1% NCT01769378
- -1.2% vs -1.1% NCT01621178
- -1.7% vs -1.2% NCT01648582
- -1.5% vs -0.9% NCT01644500
- -1.4% vs -1.4% NCT01624259
- -1.1% vs -1.1% NCT01621178
- -1.3% vs -1.2% NCT01648582
- -1.2% vs -0.9% NCT01644500
- -1.4% vs -0.9% NCT01584232
- -1% vs 0.5% NCT02963766
- -0.5% vs 0.5% NCT02963766
- -0.9% vs -1.7% NCT04255433
- -1.1% vs -1% NCT01621178
- -1.5% vs -0.9% NCT01648582
- -1.1% vs -1% NCT01621178
- -1.0% vs -0.9% NCT01648582
- -1.4% vs -0.4% NCT02973100
- -1.3% vs -0.4% NCT02973100
- -1.2% vs -0.4% NCT02973100
- -1.4% vs 0.1% NCT02750410
- Semaglutide (Ozempic)
- -1.6% vs 0%−1.6 vs placeboNCT02054897
35 other results
- -1.9% vs -0.1% NCT02305381
- -1.6% vs -0.2% NCT03086330
- -1.5% vs 0% NCT02054897
- -1.4% vs -0.1% NCT02305381
- -1.5% vs -0.9% NCT01885208
- -1.6% vs -0.6% NCT01930188
- -1.8% vs -1.1% NCT02648204
- -1.6% vs -0.8% NCT02128932
- -1.7% vs -1.1% NCT03191396
- -1.3% vs -0.6% NCT01930188
- -1.5% vs -1.1% NCT02648204
- -1.2% vs -0.8% NCT02128932
- -1.5% vs -1.2% NCT03689374
- -1.4% vs -0.7% NCT05514535
- -1.4% vs -0.4% NCT01720446
- -1.1% vs -0.4% NCT01720446
- -0.9% vs -0.0% NCT03819153
- -1.8% vs -0.3% NCT05649137
- -0.8% vs 0.2% NCT04560998
- -2.0% vs -0.7% NCT02207374
- -2.2% vs -0.7% NCT02254291
- -1.7% vs -0.7% NCT02207374
- -1.9% vs -0.7% NCT02254291
- -1.4% vs -0.7% NCT05514535
- -1.9% vs -1.1% NCT05486065
- -1.1% vs -0.4% NCT05144984
- -2.1% vs -1.1% NCT05486065
- -1.8% vs -1.1% NCT05486065
- -2.3% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.3% vs -0.4% NCT05144984
- -0.5% vs 0% NCT04538352
- -1.5% vs -1.1% NCT03596450
- -1.4% vs -1.0% NCT03596450
Body weight, change (kg)
- dulaglutide
- -0.8 vs 0.4−1.2 vs placeboNCT04591626
18 other results
- -1.9 vs 0.5 NCT02152371
- -0.9 vs -0.2 NCT01769378
- -2.7 vs 1.6 NCT01621178
- -1.1 vs 1.4 NCT01648582
- -2.8 vs 1.1 NCT01621178
- -1.5 vs 1.0 NCT01648582
- -1.5 vs 0.9 NCT01644500
- -2.9 vs -3.6 NCT01624259
- -1.7 vs 1.6 NCT01621178
- -0.8 vs 1.4 NCT01648582
- -2.0 vs 1.1 NCT01621178
- -0.9 vs 1.0 NCT01648582
- -0.8 vs 0.9 NCT01644500
- -0.5 vs 0.9 NCT01584232
- -4.1 vs -1.6 NCT02973100
- -3.9 vs -1.6 NCT02973100
- -2.8 vs -1.6 NCT02973100
- -0.2 vs -0.3 NCT02750410
- Semaglutide (Ozempic)
- -4.9 vs -0.6−4.3 vs placeboNCT01720446
32 other results
- -3.6 vs -0.6 NCT01720446
- -5.5 vs -1.4 NCT03819153
- -4.7 vs -0.9 NCT02054897
- -6.4 vs -1.4 NCT02305381
- -4.7 vs -1 NCT03086330
- -3.7 vs -0.9 NCT02054897
- -3.7 vs -1.4 NCT02305381
- -14.9 vs -4.6 NCT05649137
- -5.2 vs -1.2 NCT04560998
- -5.6 vs -1.9 NCT01885208
- -6.1 vs -1.9 NCT01930188
- -6.5 vs -2.3 NCT02648204
- -5.2 vs 1.1 NCT02128932
- -5.8 vs -2 NCT03191396
- -4.3 vs -1.9 NCT01930188
- -3.5 vs 1.1 NCT02128932
- -4.2 vs 2.9 NCT03689374
- -4.2 vs -0.4 NCT03061214
- -4.6 vs -2.3 NCT02648204
- -3 vs -0.4 NCT03061214
- -5.7 vs -4.3 NCT03136484
- -8.0 vs 0.4 NCT05514535
- -8.9 vs -2.3 NCT05486065
- -4.7 vs -2.6 NCT05144984
- -13.1 vs -2.3 NCT05486065
- -10.1 vs -2.3 NCT05486065
- -8.9 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -10 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -5 vs -3.1 NCT03596450
- -8.6 vs 1.4 NCT04538352
HbA1c below 7%
- dulaglutide
- 75.9% vs 33.8%+42.1 vs placeboNCT04591626
8 other results
- 32.9% vs 29.1% NCT01621178
- 37.5% vs 34.6% NCT01621178
- 33.5% vs 29.1% NCT01621178
- 31.7% vs 34.6% NCT01621178
- 68.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 0% vs 47.4% NCT02750410
- Semaglutide (Ozempic)
- 72.3% vs 24.8%+47.5 vs placeboNCT02054897
10 other results
- 78.6% vs 10.5% NCT02305381
- 82.5% vs 20.5% NCT03086330
- 74.2% vs 24.8% NCT02054897
- 60.6% vs 10.5% NCT02305381
- 78.7% vs 52.2% NCT02648204
- 84% vs 49.6% NCT03061214
- 80.4% vs 45.9% NCT03191396
- 68.4% vs 52.2% NCT02648204
- 74.5% vs 49.6% NCT03061214
- 76.1% vs 50.8% NCT03136484
Fasting plasma glucose, change
- dulaglutide
- -2.2 vs -2.4vs Insulin GlargineNCT01648582
3 other results
- -2.4 vs -2.6 NCT01648582
- -1.5 vs -2.4 NCT01648582
- -1.7 vs -2.6 NCT01648582
- Semaglutide (Ozempic)
- -2.1 vs -0.9−1.2 vs placeboNCT01720446
24 other results
- -1.8 vs -0.9 NCT01720446
- -2.4 vs -0.6 NCT02054897
- -2.4 vs -0.5 NCT02305381
- -2.3 vs 0.1 NCT03086330
- -2.4 vs -0.6 NCT02054897
- -1.6 vs -0.5 NCT02305381
- -3.3 vs -1.1 NCT05649137
- -2.8 vs -2 NCT01885208
- -2.6 vs -1.1 NCT01930188
- -2.8 vs -1.9 NCT02648204
- -2.7 vs -2.1 NCT02128932
- -2.6 vs -1 NCT03061214
- -2.6 vs -1.5 NCT03191396
- -2.1 vs -1.1 NCT01930188
- -2.2 vs -1.9 NCT02648204
- -2.0 vs -2.1 NCT02128932
- -1.3 vs -0.8 NCT03689374
- -2.2 vs -1 NCT03061214
- -2.5 vs -2 NCT03136484
- -1.4 vs -0.1 NCT05144984
- -3.9 vs -0.1 NCT05144984
- -3.4 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
3-point MACE (% with event)
- dulaglutide
- 12% vs 13.4%−1.4 vs placeboNCT01394952
1 other result
- 13.1% vs 12.2% NCT04255433
- Semaglutide (Ozempic)
- 6.6% vs 8.9%−2.3 vs placeboNCT01720446
1 other result
- 12% vs 14.4% NCT03819153
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. dulaglutide: 10 of 10 rows · Semaglutide (Ozempic): 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dulaglutide Rows use multiple source trials | Semaglutide (Ozempic) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -0.4 vs 0.52 Insulin Glargine kg @ 52wk1.5 mga,b,c NCT01648582 · Phase 3 · registry result, not featured evidence show 1 more dose-0.27 vs 0.52 Insulin Glargine kg @ 52wk0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence | -1.5 vs 1 Insulin Aspart kg @ 52wkb,c NCT03689374 · Phase 3 · registry result, not featured evidence 1 other source trial-2 vs -1.5 Canagliflozin kg @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c absolute change · percentage points No placebo or comparator arm | -1.5% (n=383) @ 52wk1.5 mga,b,c NCT04809220 · Phase 3 · registry result, not featured evidence show 1 more dose-1.19% (n=193) @ 52wk0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence | -1.23% (n=91) @ 52wkb,c NCT05813912 · Phase 3 · registry result, not featured evidence · combination 1 other source trial-0.86% (n=335) @ 52wk NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain responder rate · % of participants | 51.8% (n=139) vs 21.1% (n=147) placebo @ 28wk1.5 mgd,b,e,f NCT04591626 · Phase 3 · registry result, not featured evidence · add on | 69.6% (n=293) vs 45% (n=313) Canagliflozin @ 52wkd,b,e,f Yes NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 71.48% (n=526) @ 36wk4.5 mga,b,c,g NCT03495102 · Phase 3 show 2 more doses64.68% (n=521) @ 36wk3 mg NCT03495102 · Phase 3 56.98% (n=523) @ 36wk1.5 mg NCT03495102 · Phase 3 | 67.6% (n=480) @ 40wk2.0 mg weeklya,b,c,g NCT03989232 · Phase 3 show 1 more dose57.5% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| Weight percent change · % of baseline | -4.82% (n=6578) vs -11.6% (n=6586) Tirzepatide @ 156wk1.5 mgh,b,c,i NCT04255433 · Phase 3 · registry result, not featured evidence | -4.47% (n=389) vs -2.68% (n=386) Standard of Care @ 104wkh,b,c,i NCT03596450 · Phase 4 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -0.5 kg @ 52wk1.5 mga,b,c NCT04809220 · Phase 3 · registry result, not featured evidence show 1 more dose-0.2 kg @ 52wk0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence | -3.85 kg @ 52wkb,c NCT05813912 · Phase 3 · registry result, not featured evidence · combination 1 other source trial-3.77 kg @ 52wk NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Dropout rate | 0.3%j NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results4.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.8%4.5 mg NCT03495102 · Phase 3 10.9%3 mg NCT03495102 · Phase 3 9.2%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 3.8%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 3.9%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 2.5%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence 2.2%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.1%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 4.9%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 3.5%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 8% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 12.4%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 14.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 10.4% NCT01769378 · Phase 3 · registry result, not featured evidence 9%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 9.7%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 10%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 9.2%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 5.1%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 16.7% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 1.3%1.0 mgk NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results1.7%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.4% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 7.8%0.5 mg weekly NCT02054897 · Phase 3 5.1%1.0 mg weekly NCT01930188 · Phase 3 · combination 5.4%0.5 mg weekly NCT01930188 · Phase 3 · combination 5.3%1.0 mg/week NCT02128932 · Phase 3 7.5%0.5 mg/week NCT02128932 · Phase 3 3.8%2.0 mg weekly NCT03989232 · Phase 3 2.1%1.0 mg weekly NCT03989232 · Phase 3 3.8%1.0 mg weekly NCT02305381 · Phase 3 3.8%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 10.6% NCT05533632 · Phase 4 · registry result, not featured evidence 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 28.1% NCT03596450 · Phase 4 · registry result, not featured evidence 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination 1.7%Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 3.9%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 18.3%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 7.6% NCT04560998 · Phase 3 · registry result, not featured evidence 1.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence 9.7%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 8.7%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.9% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 2.6%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 7.3%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 4.1%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.5%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.9%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 8.2%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 11.3%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 12.9%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 3.9%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.7%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —j NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results1.7% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%4.5 mg NCT03495102 · Phase 3 1.1%3 mg NCT03495102 · Phase 3 0.8%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 0%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 1.7%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence —1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.4%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 4% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 2.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.3%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.2% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 0.4%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 6%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 2.6%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 1.3%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 8.3% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | —1.0 mgk NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results—0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT03819153 · Phase 3 —1.0 mg weekly NCT02054897 · Phase 3 —0.5 mg weekly NCT02054897 · Phase 3 —1.0 mg weekly NCT01930188 · Phase 3 · combination —0.5 mg weekly NCT01930188 · Phase 3 · combination —1.0 mg/week NCT02128932 · Phase 3 —0.5 mg/week NCT02128932 · Phase 3 —2.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT02305381 · Phase 3 —0.5 mg weekly NCT02305381 · Phase 3 — NCT04126603 · Phase 4 · registry result, not featured evidence — NCT05786521 · Phase 4 · registry result, not featured evidence 3.8% NCT05533632 · Phase 4 · registry result, not featured evidence —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 2.2% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination —7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence —1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence — NCT04560998 · Phase 3 · registry result, not featured evidence — NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence —0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence — NCT03136484 · Phase 3 · registry result, not featured evidence · combination —1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 0%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence —2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence —2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 40.3%j NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results5% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%4.5 mg NCT03495102 · Phase 3 7.3%3 mg NCT03495102 · Phase 3 8.7%1.5 mg NCT03495102 · Phase 3 21.4%1.5 mg NCT01621178 · Phase 3 25.3%0.75 mg NCT01621178 · Phase 3 —1.5 mg NCT02963766 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 4%1.5 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 0%1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence 0%0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence 2.5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence 0% NCT03315780 · Phase 4 · registry result, not featured evidence 31.9%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence 3.8%1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.6%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence 5.6%1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 3.5%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 2.1%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 6% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 9.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 5.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 3.8% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.6%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.7%1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence —LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 3.9%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 8.9%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence 3.7%1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 9.1%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0% NCT01458210 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 0% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 33.6%1.0 mgk NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results35%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 9.4%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 49.6% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 5.5%0.5 mg weekly NCT02054897 · Phase 3 7.3%1.0 mg weekly NCT01930188 · Phase 3 · combination 7.3%0.5 mg weekly NCT01930188 · Phase 3 · combination 4.7%1.0 mg/week NCT02128932 · Phase 3 6.1%0.5 mg/week NCT02128932 · Phase 3 4.4%2.0 mg weekly NCT03989232 · Phase 3 5.2%1.0 mg weekly NCT03989232 · Phase 3 9.2%1.0 mg weekly NCT02305381 · Phase 3 6.1%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 1% NCT05533632 · Phase 4 · registry result, not featured evidence 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 6% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 5.9%INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 9.8%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 19.7%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 18.7% NCT04560998 · Phase 3 · registry result, not featured evidence 6.2% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 7.4% NCT03689374 · Phase 3 · registry result, not featured evidence 6.6%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.3%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 4.6% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 5.9%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 4.7%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7.7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5.6%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 7.9%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 5.8%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 6.7%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 1.6%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.3%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 2.6%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 7.8%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 6.5%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 4.1%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | j nausea 14.9% (placebo 5.4%) diarrhoea 13.5% (placebo 8.8%) nasopharyngitis 11.4% (placebo 10.8%) NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 41 more resultsnasopharyngitis 27.1% diarrhoea 12.2% nausea 9.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5 mg diarrhoea 21.2% (placebo 13.7%) headache 15.4% (placebo 9.8%) nausea 15.4% (placebo 7.8%) NCT02963766 · Phase 3 1.5 mg diarrhoea 12% (placebo 13.7%) nausea 12% (placebo 7.8%) abdominal pain upper 10% (placebo 7.8%) NCT02963766 · Phase 3 0.75 mg vomiting 17.6% (placebo 3.9%) diarrhoea 15.7% (placebo 13.7%) headache 13.7% (placebo 9.8%) NCT02963766 · Phase 3 0.75 mg headache 10.2% (placebo 9.8%) vomiting 8.2% (placebo 3.9%) abdominal pain 6.1% (placebo 5.9%) NCT02963766 · Phase 3 1.5 mg gastritis 14.3% dyslipidaemia 9.5% nausea 9.5% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg anaemia 21.4% gastritis 14.3% dyslipidaemia 7.1% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 15.8% (placebo 30.8%) abdominal discomfort 8.3% (placebo 12.8%) constipation 6.7% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 28.3% (placebo 30.8%) constipation 10.8% (placebo 12.8%) abdominal discomfort 9.2% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence influenza 16.7% (placebo 0%) decreased appetite 8.3% (placebo 0%) diarrhoea 8.3% (placebo 8.3%) NCT03315780 · Phase 4 · registry result, not featured evidence 1.5 mg nausea 22.3% diarrhoea 18.9% covid-19 15.1% NCT04255433 · Phase 3 · registry result, not featured evidence 1.5 mg constipation 12.5% diarrhoea 10.2% pyrexia 10% NCT04809220 · Phase 3 · registry result, not featured evidence 0.75 mg constipation 8.7% nasopharyngitis 8.7% covid-19 8.2% NCT04809220 · Phase 3 · registry result, not featured evidence 1.5 mg decreased appetite 22.2% (placebo 4.1%) diabetic nephropathy 13.9% (placebo 15%) diarrhoea 13.2% (placebo 8.2%) NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.5 mg nausea 14.8% (placebo 3.6%) back pain 9.2% (placebo 7.1%) viral upper respiratory tract infection 6.3% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence 0.75 mg diarrhoea 9.9% (placebo 2.9%) back pain 8.5% (placebo 7.1%) viral upper respiratory tract infection 5.7% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence nausea 12% (placebo 1.3%) diarrhoea 11.3% (placebo 4%) upper respiratory tract infection 7.3% (placebo 6.7%) NCT02152371 · Phase 3 · registry result, not featured evidence · combination 1.5 mg hyperlipidaemia 17.8% diarrhoea 16.7% lipase increased 10.5% NCT01648582 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 19.5% diarrhoea 10.9% hypertension 10.9% NCT01648582 · Phase 3 · registry result, not featured evidence nausea 10.5% (placebo 0%) diarrhoea 8.4% (placebo 0%) eructation 5.9% (placebo 0%) NCT01769378 · Phase 3 · registry result, not featured evidence 1.5 mg diarrhoea 17.2% hyperlipidaemia 11.1% nausea 10.2% NCT01644500 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 12.1% diarrhoea 7.3% lipase increased 5.6% NCT01644500 · Phase 3 · registry result, not featured evidence 1.5 mg weekly nausea 20.4% diarrhoea 12% dyspepsia 8% NCT01624259 · Phase 3 · registry result, not featured evidence 4.5 mg nausea 30.3% (placebo 4.9%) diarrhoea 21.1% (placebo 11.1%) vomiting 13.2% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 3.0 mg nausea 25.3% (placebo 4.9%) diarrhoea 22.8% (placebo 11.1%) decreased appetite 16.5% (placebo 1.2%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg nausea 22.2% (placebo 4.9%) diarrhoea 11.1% (placebo 11.1%) vomiting 11.1% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) blood pressure decreased 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 1.5 mg abdominal discomfort 10% (placebo 6.3%) decreased appetite 10% (placebo 0%) nausea 10% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg abdominal discomfort 9.1% (placebo 6.3%) nausea 9.1% (placebo 0%) vomiting 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal distension 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg abdominal discomfort 0% (placebo 6.3%) abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal pain 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence headache 41.2% nausea 41.2% vomiting 35.3% NCT01458210 · Phase 1 · registry result, not featured evidence · combination diarrhoea 8% haemorrhoids 4% injection site pain 4% NCT01432938 · Phase 1 · registry result, not featured evidence · combination vomiting 11.5% decreased appetite 7.7% headache 7.7% NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy gastrooesophageal reflux disease 33.3% atrioventricular block first degree 28.6% headache 28.6% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 1.0 mgk nausea 21.8% (placebo 7.5%) diarrhoea 18% (placebo 11.8%) vomiting 14.8% (placebo 5.1%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 42 more results0.5 mg diarrhoea 17.9% (placebo 11.8%) nausea 17.3% (placebo 7.5%) lipase increased 11.4% (placebo 8%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 1.0 mg nausea 22.3% diarrhoea 11.4% lipase increased 10.1% NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.0 mg weekly nausea 23.8% (placebo 7.8%) diarrhoea 10.8% (placebo 2.3%) headache 6.9% (placebo 6.2%) NCT02054897 · Phase 3 0.5 mg weekly nausea 20.3% (placebo 7.8%) diarrhoea 12.5% (placebo 2.3%) headache 11.7% (placebo 6.2%) NCT02054897 · Phase 3 1.0 mg weekly nausea 16.8% (placebo 4.5%) vomiting 11.5% (placebo 3%) diarrhoea 6.9% (placebo 1.5%) NCT02305381 · Phase 3 0.5 mg weekly nausea 11.4% (placebo 4.5%) lipase increased 9.1% (placebo 3%) nasopharyngitis 8.3% (placebo 10.5%) NCT02305381 · Phase 3 abdominal pain 60% NCT05786521 · Phase 4 · registry result, not featured evidence once weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nausea 18.4% diarrhoea 13.5% vomiting 9.7% NCT05514535 · Phase 3 · registry result, not featured evidence · combination 7.2 mg nausea 29% (placebo 11.8%) diarrhoea 18.2% (placebo 8.8%) vomiting 16.6% (placebo 2.9%) NCT05649137 · Phase 3 · registry result, not featured evidence 1.0 mg covid-19 5.6% (placebo 0%) decreased appetite 5.6% (placebo 0%) diabetic retinopathy 5.6% (placebo 5.7%) NCT04865770 · Phase 3 · registry result, not featured evidence covid-19 7.6% (placebo 5.3%) nausea 5.6% (placebo 0.8%) NCT04560998 · Phase 3 · registry result, not featured evidence covid-19 14.4% diarrhoea 12.1% nausea 11.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nausea 14.8% diarrhoea 7.4% nasopharyngitis 6.5% NCT03689374 · Phase 3 · registry result, not featured evidence 1.0 mg weekly diarrhoea 16.9% nausea 13.4% upper respiratory tract infection 13.1% NCT03061214 · Phase 3 · registry result, not featured evidence 0.5 mg weekly diarrhoea 20.2% upper respiratory tract infection 9.8% lipase increased 7.7% NCT03061214 · Phase 3 · registry result, not featured evidence nausea 22.7% diarrhoea 15.1% vomiting 12.8% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1.0 mg nausea 21.5% diarrhoea 15.6% decreased appetite 10.4% NCT03191396 · Phase 3 · registry result, not featured evidence 1.0 mg weekly nausea 19.3% (placebo 3.3%) diarrhoea 11.3% (placebo 6%) vomiting 9.3% (placebo 2%) NCT03086330 · Phase 3 · registry result, not featured evidence 1.0 mg nausea 21% diarrhoea 13.7% vomiting 10.3% NCT02648204 · Phase 3 · registry result, not featured evidence 0.5 mg nausea 22.3% diarrhoea 14.3% vomiting 10% NCT02648204 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 31.1% nausea 19.1% diarrhoea 15.8% NCT02207374 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 33.9% constipation 18.4% nausea 12.1% NCT02207374 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 17.6% nausea 12.7% constipation 11.8% NCT02254291 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 16.5% constipation 14.6% nausea 10.7% NCT02254291 · Phase 3 · registry result, not featured evidence 2.0 mg nausea 21.7% (placebo 15.3%) vomiting 18.3% (placebo 6.8%) diarrhoea 15% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 16.0 mg nausea 37.1% (placebo 15.3%) vomiting 25.8% (placebo 6.8%) diarrhoea 21% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 8.0 mg nausea 41.7% (placebo 15.3%) diarrhoea 33.3% (placebo 11.9%) vomiting 23.3% (placebo 6.8%) NCT05486065 · Phase 2 · registry result, not featured evidence 21.6 mg injection site erythema 10.2% (placebo 0%) injection site reaction 10.2% (placebo 0%) diarrhoea 8.5% (placebo 11.5%) NCT05144984 · Phase 2 · registry result, not featured evidence 2.4 mg + 12.0 mg diarrhoea 14.3% (placebo 11.5%) constipation 9.1% (placebo 1.6%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 2.4 mg nausea 19.5% (placebo 1.6%) diarrhoea 14.3% (placebo 11.5%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 21.6 mg diarrhoea 13% (placebo 11.5%) nausea 13% (placebo 1.6%) covid-19 11.7% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 7.2 mg diarrhoea 21.6% (placebo 11.5%) lipase increased 12.2% (placebo 3.3%) nausea 12.2% (placebo 1.6%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe reported result categories differ.
- eTreatment context differs: combination versus add on.
- fAssessment timepoints differ: 52 weeks versus 28 weeks.
- gAssessment timepoints differ: 40 weeks versus 36 weeks.
- hTrial phases differ: Phase 4 versus Phase 3.
- iAssessment timepoints differ: 104 weeks versus 156 weeks.
- jPopulation comparability has not been reviewed for 44 of these studies.
- kPopulation comparability has not been reviewed for 43 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dulaglutide
show 4 more results
show 3 more results
show 1 more result
show 2 more results
show 4 more results
show 3 more results
+ 54 further endpoints in the CSV export.
Semaglutide (Ozempic)
show 13 more results
show 7 more results
show 10 more results
show 1 more result
+ 108 further endpoints in the CSV export.
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: December 2030 · NCT07282041 (registry estimate)
Reported efficacy
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 (met)
Result source: NCT01394952
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: July 2028 · NCT07073053 (registry estimate)
Reported efficacy
Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)
Result source: NCT04560998
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dulaglutide | Semaglutide (Ozempic) |
|---|---|---|
| LDL-C, % change | —Trial running · NCT07282041 | —Not reported |
| Non-HDL-C, % change | —Trial running · NCT07282041 | —Not reported |
| ApoB, % change | —Trial running · NCT07282041 | —Not reported |
| Lp(a), % change | —Trial running · NCT07282041 | —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT07282041 | —Not reported |
LDL-C, % change
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Ozempic)
- —Not reported
Non-HDL-C, % change
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Ozempic)
- —Not reported
ApoB, % change
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Ozempic)
- —Not reported
Lp(a), % change
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Ozempic)
- —Not reported
3-point MACE (% with event)
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Ozempic)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. dulaglutide: 0 of 4 rows · Semaglutide (Ozempic): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Ozempic) |
|---|---|
| Dropout rate | 7.6%a NCT04560998 · Phase 3 |
| Discontinued due to AEs | —a NCT04560998 · Phase 3 |
| Serious AEs | 18.7%a NCT04560998 · Phase 3 |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Ozempic)
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Semaglutide (Ozempic)'s landscape